Tarsus Pharmaceuticals Earnings Call Signals Durable Growth

Tarsus Pharmaceuticals, Inc. ((TARS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tarsus Pharmaceuticals’ latest earnings call struck an optimistic tone as management highlighted strong momentum for XTENVI and reaffirmed full‑year guidance despite seasonal headwinds. Executives pointed to robust prescription trends, rising retreatment rates, and promising pipeline progress as key drivers underpinning confidence in long‑term growth targets.

XTENVI Delivers Another Quarter of Breakout Growth

XTENVI net product sales climbed to $145.4 million in Q1 2026, representing more than 85% year‑over‑year growth and underscoring accelerating adoption. Management tied the performance to expanding use among eye care professionals and consistent real‑world outcomes that are helping embed the therapy in routine practice.

Guidance Reaffirmed as Profitability Metrics Stay Strong

Tarsus reiterated full‑year 2026 guidance for XTENVI net product sales of $670 million to $700 million, signaling confidence in the durability of demand. The company continues to target gross margins of about 93%, with SG&A of $545 million to $565 million and R&D of $115 million to $135 million, including planned stock‑based compensation.

Prescriber Base Deepens as Weekly Use Expands

Nearly half of the company’s 15,000 target eye care professionals are now prescribing XTENVI at least once a week, up roughly 10% from Q4 2025 and reflecting broadening comfort with the product. Tarsus also reported increasing depth of prescribing, with mid‑to‑high‑teens retreatment rates progressing toward its roughly 20% steady‑state goal.

DTC Campaigns and Digital Funnel Show Compounding Effects

Management highlighted that its direct‑to‑consumer campaign is delivering returns at the high end of industry benchmarks, supporting sustained demand generation. High‑value engagement on xtenvi.com, such as quiz completions and doctor searches, rose nearly 40% quarter over quarter, with millions of visitors widening the top of the patient funnel.

Pipeline Advances with Two Phase II Programs Underway

Tarsus launched the CALLIOPE Phase II trial of TPO5, enrolling about 700 participants to evaluate a potential Lyme disease prevention therapy with top‑line data expected in 2027. The company also initiated the Phase II CORE study of TPO4 in ocular rosacea, another 2027 data event that could diversify the portfolio beyond XTENVI.

China Milestone Boosts Revenue, Signals Future Optionality

License and collaboration revenue reached $16.7 million in Q1, driven largely by a $15 million regulatory milestone from partner Grand Pharma following approval of TPO3 for DB in Greater China. While not a near‑term earnings driver, management framed the region as a longer‑term royalty and commercial expansion opportunity.

Sales Force Strategy Evolves with Key Account Focus

To deepen penetration in high‑value practices, Tarsus plans to add roughly 17 to 20 Key Account Leaders starting in the third quarter of 2026. The company expects this more targeted commercial model to begin delivering incremental prescription growth in the second half of the year as relationships mature.

XTENVI Outperforms Peers Amid Market Volatility

Management said XTENVI outpaced competing products on prescription trends, with peers experiencing double‑digit declines while Tarsus saw only low‑single‑digit softness in comparable metrics. Demand has already rebounded, and entering the second quarter, prescriptions were described as reaching all‑time highs.

Seasonality, Deductibles, and Weather Weigh on Q1

The company noted that first‑quarter results were dampened by typical seasonal patterns, including deductible resets and higher patient out‑of‑pocket costs. Severe winter weather, particularly in the Northeast, further constrained visit volumes, though management emphasized that these factors did not reflect underlying demand trends.

Retreatment Rates Still Climbing Toward Revenue Steady State

Retreatment rates remain in the mid‑to‑high teens and continue to rise quarter over quarter, but have yet to reach the company’s roughly 20% steady‑state expectation. Because retreatment is a key driver of recurring revenue, investors will be watching whether these rates converge on management’s target over the next several quarters.

One‑Time Milestone Highlights Non‑Recurring Revenue Risk

Tarsus underscored that the $16.7 million in license and collaboration revenue included a largely non‑recurring $15 million milestone tied to regulatory approval in Greater China. Future royalties from that partnership are not expected to be material in 2026 or 2027, limiting the near‑term contribution from international licensing.

Global Expansion Clouded by Access and Geopolitics

International upside remains constrained as Grand Pharma must still secure payer coverage in Greater China before royalty streams become meaningful. More broadly, Tarsus is taking a cautious approach to additional global filings, citing geopolitical, regulatory, and market access uncertainties that could affect timing and economics.

Reduced Disclosure Adds a Layer of Opacity

Management has moved away from sharing quarterly bottles‑dispensed figures and detailed gross‑to‑net metrics, focusing instead on full‑year guidance. While this may simplify internal reporting, it reduces granularity for investors and analysts who had relied on those datapoints to model near‑term trends.

Lyme Disease Program Likely to Require a Partner

For TPO5 in Lyme disease, Tarsus views partnership as the base‑case path for a Phase III program, which could resemble a large, vaccine‑style prevention trial. That strategy could mitigate financial and operational burden but introduces execution risk tied to finding the right partner and aligning on trial design and timelines.

Guidance and Growth Cadence Point to Strong Second Half

Management reaffirmed 2026 financial guidance and outlined an expected growth pattern of a strong second quarter, more modest third quarter, and robust fourth quarter. With retreatment rates rising, key account leaders coming online, digital engagement building, and two Phase II programs progressing toward 2027 readouts, Tarsus reiterated its long‑term aspiration of achieving roughly $2 billion in peak sales.

Tarsus’ earnings call painted a picture of a company in commercial scale‑up mode, with XTENVI driving outsized growth amid manageable headwinds. While disclosure changes, international uncertainty, and development partnerships introduce new variables, the overall message to investors was one of steady execution today and multiple levers for durable expansion tomorrow.